{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:13:44Z","timestamp":1791119624672,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":4422,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1093\/annonc\/mdm086","type":"journal-article","created":{"date-parts":[[2007,4,11]],"date-time":"2007-04-11T04:04:03Z","timestamp":1176264243000},"page":"1765-1773","source":"Crossref","is-referenced-by-count":151,"title":["The role of Src in prostate cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"K.","family":"Fizazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm086_bb0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.cellbio.13.1.513","article-title":"Cellular functions regulated by Src family kinases","volume":"13","author":"Thomas","year":"1997","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1093\/annonc\/mdm086_bb0015","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for Src","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1093\/annonc\/mdm086_bb0025","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/35073094","article-title":"The hunting of the Src","volume":"2","author":"Martin","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1093\/annonc\/mdm086_bb0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/08977190500178877","article-title":"C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)\u2014endogenous negative regulators of Src-family protein kinases","volume":"23","author":"Chong","year":"2005","journal-title":"Growth Factors"},{"key":"10.1093\/annonc\/mdm086_bb0035","doi-asserted-by":"crossref","first-page":"7957","DOI":"10.1038\/sj.onc.1208079","article-title":"The interplay between Src family kinases and receptor tyrosine kinases","volume":"23","author":"Bromann","year":"2004","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdm086_bb0040","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1074\/jbc.273.1.577","article-title":"SH2- and SH3-mediated interactions between focal adhesion kinase and Src","volume":"273","author":"Thomas","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdm086_bb0045","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1128\/MCB.20.16.5865-5878.2000","article-title":"Regulation of c-Src activity and function by the adapter protein CAS","volume":"20","author":"Burnham","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdm086_bb0050","doi-asserted-by":"crossref","first-page":"13754","DOI":"10.1016\/S0021-9258(18)67084-X","article-title":"Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues","volume":"261","author":"Rosen","year":"1986","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdm086_bb0055","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1073\/pnas.84.8.2251","article-title":"Activation of pp60c-src protein kinase activity in human colon carcinoma","volume":"84","author":"Bolen","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdm086_bb0060","first-page":"357","article-title":"Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines","volume":"1","author":"Veillette","year":"1987","journal-title":"Oncogene Res"},{"key":"10.1093\/annonc\/mdm086_bb0065","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s004320000197","article-title":"Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue","volume":"127","author":"Reissig","year":"2001","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdm086_bb0070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1006\/bbrc.1997.8043","article-title":"Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma","volume":"243","author":"Lutz","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdm086_bb0075","first-page":"2627","article-title":"c-Yes tyrosine kinase activity in human colon carcinoma","volume":"8","author":"Park","year":"1993","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdm086_bb0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1172\/JCI116200","article-title":"Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer","volume":"91","author":"Talamonti","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdm086_bb0085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/jsre.1993.1046","article-title":"Site-specific differences in pp60c-src activity in human colorectal metastases","volume":"54","author":"Termuhlen","year":"1993","journal-title":"J Surg Res"},{"key":"10.1093\/annonc\/mdm086_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.10221","article-title":"Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis","volume":"94","author":"Aligayer","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0095","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdm086_bb0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1093\/annonc\/mdm086_bb0105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1535-6108(03)00089-8","article-title":"PDGF receptors as cancer drug targets","volume":"3","author":"Pietras","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdm086_bb0110","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"Harari","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0115","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/0140-6736(93)92881-S","article-title":"Expression of focal adhesion kinase gene and invasive cancer","volume":"342","author":"Weiner","year":"1993","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm086_bb0120","first-page":"2752","article-title":"Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors","volume":"55","author":"Owens","year":"1995","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/5971","article-title":"Activating Src mutation in a subset of advanced human colon cancers","volume":"21","author":"Irby","year":"1999","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdm086_bb0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1349-7006.2000.tb00958.x","article-title":"Mutation of the Src gene in endometrial carcinoma","volume":"91","author":"Sugimura","year":"2000","journal-title":"Jpn J Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0165-4608(00)00226-0","article-title":"Lack of activating c-Src mutations at codon 531 in rectal cancer","volume":"121","author":"Nilbert","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1093\/annonc\/mdm086_bb0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0304-3835(99)00398-5","article-title":"No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese","volume":"150","author":"Wang","year":"2000","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdm086_bb0145","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1054\/bjoc.2000.1560","article-title":"Lack of mutation at codon 531 of Src in advanced colorectal cancers from Italian patients","volume":"84","author":"Laghi","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0150","first-page":"4222","article-title":"Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients","volume":"59","author":"Daigo","year":"1999","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0155","doi-asserted-by":"crossref","first-page":"41439","DOI":"10.1074\/jbc.M004852200","article-title":"Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines","volume":"275","author":"Bjorge","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdm086_bb0160","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4","article-title":"Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression","volume":"88","author":"Yip","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D","article-title":"Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma","volume":"92","author":"Cam","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0170","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep.510290239","article-title":"Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma","volume":"29","author":"Masaki","year":"1999","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdm086_bb0175","doi-asserted-by":"crossref","first-page":"9185","DOI":"10.1158\/0008-5472.CAN-05-1731","article-title":"Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells","volume":"65","author":"Nam","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0180","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/0008-5472.CAN-03-2420","article-title":"Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts","volume":"64","author":"Goldenberg-Furmanov","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0185","article-title":"Survey of Src activity and Src-related growth and migration in prostate cancer lines","volume":"47","author":"Chang","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0190","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0959-8049(03)00394-0","article-title":"Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro","volume":"39","author":"Recchia","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0195","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/sj.onc.1204208","article-title":"Alterations in the focal adhesion kinase\/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells","volume":"20","author":"Slack","year":"2001","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdm086_bb0200","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1093\/annonc\/mdm086_bb0205","first-page":"6145","article-title":"Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest","volume":"59","author":"Moasser","year":"1999","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0210","first-page":"159","article-title":"BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo","volume":"46","author":"Lee","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"June 20 Suppl","key":"10.1093\/annonc\/mdm086_bb0215","first-page":"640s","article-title":"Activity of the Src-kinase inhibitor AZD0530 in androgen-independent prostate cancer (AIPC): pre-clinical rationale for a phase II trial","volume":"24","author":"Evans","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1093\/annonc\/mdm086_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6349(04)80149-6","article-title":"The spectrum-selective kinase inhibitor EXEL0999 inhibits mitogenic and angiogenic kinases, and causes rapid tumor vasculature destruction and regression in mouse xenograft models","volume":"2","author":"Aftab","year":"2004","journal-title":"Eur J Cancer Suppl"},{"key":"10.1093\/annonc\/mdm086_bb0225","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1093\/emboj\/19.20.5406","article-title":"Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation","volume":"19","author":"Migliaccio","year":"2000","journal-title":"EMBO J"},{"key":"10.1093\/annonc\/mdm086_bb0230","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/sj.onc.1207344","article-title":"Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK","volume":"23","author":"Lee","year":"2004","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdm086_bb0235","doi-asserted-by":"crossref","first-page":"8385","DOI":"10.1128\/MCB.21.24.8385-8397.2001","article-title":"Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk\/Bmx, Src, and focal adhesion kinase","volume":"21","author":"Lee","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdm086_bb0240","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.1158\/0008-5472.CAN-04-1121","article-title":"Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence","volume":"64","author":"Unni","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0245","first-page":"5271","article-title":"Gene amplifications associated with the development of hormone-resistant prostate cancer","volume":"9","author":"Edwards","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2003.08.011","article-title":"Smart drugs in prostate cancer","volume":"45","author":"van der Poel","year":"2004","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdm086_bb0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1534735404270757","article-title":"Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy","volume":"3","author":"McCarty","year":"2004","journal-title":"Integr Cancer Ther"},{"key":"10.1093\/annonc\/mdm086_bb0260","first-page":"3438","article-title":"Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer","volume":"8","author":"Di Lorenzo","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0265","doi-asserted-by":"crossref","first-page":"6981","DOI":"10.1073\/pnas.92.15.6981","article-title":"Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers","volume":"92","author":"Maa","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdm086_bb0270","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","article-title":"Mechanism of biological synergy between cellular Src and epidermal growth factor receptor","volume":"96","author":"Tice","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdm086_bb0275","first-page":"114","article-title":"Src in cancer: deregulation and consequences for cell behaviour","volume":"1602","author":"Frame","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1093\/annonc\/mdm086_bb0280","first-page":"1167","article-title":"Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide","volume":"3","author":"Shawver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0285","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/jnci\/95.6.458","article-title":"Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases","volume":"95","author":"Uehara","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm086_bb0290","first-page":"800","article-title":"A multi-institutional phase II study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer","volume":"7","author":"Ko","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0295","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2004.10.116","article-title":"Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer","volume":"22","author":"Mathew","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm086_bb0300","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pros.20130","article-title":"A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer","volume":"62","author":"Rao","year":"2005","journal-title":"Prostate"},{"key":"10.1093\/annonc\/mdm086_bb0305","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1464-410X.2006.06396.x","article-title":"A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy","volume":"98","author":"Lin","year":"2006","journal-title":"BJU Int"},{"issue":"June 20 Suppl","key":"10.1093\/annonc\/mdm086_bb0310","first-page":"232s","article-title":"Preliminary results of a randomized placebo-controlled double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM)","volume":"24","author":"Mathew","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1093\/annonc\/mdm086_bb0315","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1038\/sj.onc.1208513","article-title":"HIF-1alpha, STAT3, CBP\/p300 and Ref-1\/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas","volume":"24","author":"Gray","year":"2005","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdm086_bb0320","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1158\/0008-5472.CAN-04-1837","article-title":"Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells","volume":"65","author":"Pandini","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0325","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0022-5347(05)66990-X","article-title":"Essential role for G proteins in prostate cancer cell growth and signaling","volume":"164","author":"Kue","year":"2000","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdm086_bb0330","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T","article-title":"Overexpression of the EphA2 tyrosine kinase in prostate cancer","volume":"41","author":"Walker-Daniels","year":"1999","journal-title":"Prostate"},{"key":"10.1093\/annonc\/mdm086_bb0335","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0002-9440(10)63584-5","article-title":"High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia","volume":"163","author":"Zeng","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdm086_bb0340","doi-asserted-by":"crossref","first-page":"F960","DOI":"10.1152\/ajprenal.00020.2006","article-title":"Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases","volume":"291","author":"Baldwin","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1093\/annonc\/mdm086_bb0345","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1523\/JNEUROSCI.0985-04.2004","article-title":"Src family kinases are involved in EphA receptor-mediated retinal axon guidance","volume":"24","author":"Knoll","year":"2004","journal-title":"J Neurosci"},{"key":"10.1093\/annonc\/mdm086_bb0350","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W","article-title":"Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma","volume":"68","author":"Tremblay","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0355","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0002-9440(10)63212-9","article-title":"Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer","volume":"164","author":"Paronetto","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdm086_bb0360","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdm086_bb0365","first-page":"5652","article-title":"Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway","volume":"61","author":"Yang","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0370","first-page":"2587","article-title":"Prostate cancer cells-osteoblast interaction shifts expression of growth\/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts","volume":"9","author":"Fizazi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0375","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdm086_bb0380","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm086_bb0385","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdm086_bb0390","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0395","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0400","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdm086_bb0405","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000089676","article-title":"Present status and perspectives in the treatment of hormone-refractory prostate cancer","volume":"69","author":"Silvestris","year":"2005","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm086_bb0410","article-title":"A phase II trial of maintenance docetaxel and samarium in patients with castration-refractory bone metastases from prostate cancer with response or stabilization after induction docetaxel-estramustine: preliminary results","author":"Fizazi","year":"2006","journal-title":"Proceedings of the ASCO Prostate Cancer Symposium"},{"key":"10.1093\/annonc\/mdm086_bb0415","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdm086_bb0420","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","article-title":"Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice","volume":"64","author":"Soriano","year":"1991","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdm086_bb0425","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1073\/pnas.90.10.4485","article-title":"Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts","volume":"90","author":"Lowe","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdm086_bb0430","doi-asserted-by":"crossref","first-page":"17660","DOI":"10.1074\/jbc.M311032200","article-title":"Src kinase activity is essential for osteoclast function","volume":"279","author":"Miyazaki","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdm086_bb0435","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1083\/jcb.152.1.181","article-title":"Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility","volume":"152","author":"Sanjay","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1093\/annonc\/mdm086_bb0440","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1172\/JCI116032","article-title":"Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice","volume":"90","author":"Boyce","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdm086_bb0445","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1097-2765(00)80232-4","article-title":"TRANCE, a TNF family member, activates Akt\/PKB through a signaling complex involving TRAF6 and c-Src","volume":"4","author":"Wong","year":"1999","journal-title":"Mol Cell"},{"key":"10.1093\/annonc\/mdm086_bb0450","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1101\/gad.840301","article-title":"Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival","volume":"15","author":"Xing","year":"2001","journal-title":"Genes Dev"},{"key":"10.1093\/annonc\/mdm086_bb0455","doi-asserted-by":"crossref","first-page":"49343","DOI":"10.1074\/jbc.M103642200","article-title":"Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK","volume":"276","author":"Lee","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdm086_bb0460","doi-asserted-by":"crossref","first-page":"9373","DOI":"10.1073\/pnas.97.17.9373","article-title":"Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity","volume":"97","author":"Shakespeare","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdm086_bb0465","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1172\/JCI116521","article-title":"Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo","volume":"91","author":"Yoneda","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdm086_bb0470","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S8756-3282(99)00020-4","article-title":"A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo","volume":"24","author":"Missbach","year":"1999","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdm086_bb0475","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1006\/bbrc.1994.1363","article-title":"Evidence that c-src is involved in the process of osteoclastic bone resorption","volume":"199","author":"Hall","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdm086_bb0480","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bone.2003.06.004","article-title":"Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1\/2 pathway","volume":"34","author":"Recchia","year":"2004","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdm086_bb0485","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1074-5521(00)00090-9","article-title":"A Src SH2 selective binding compound inhibits osteoclast-mediated resorption","volume":"7","author":"Violette","year":"2000","journal-title":"Chem Biol"},{"key":"10.1093\/annonc\/mdm086_bb0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S8756-3282(00)00427-0","article-title":"Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption","volume":"28","author":"Violette","year":"2001","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdm086_bb0495","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1083\/jcb.151.2.311","article-title":"Decreased c-Src expression enhances osteoblast differentiation and bone formation","volume":"151","author":"Marzia","year":"2000","journal-title":"J Cell Biol"},{"key":"10.1093\/annonc\/mdm086_bb0500","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/jpet.106.102004","article-title":"Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy","volume":"318","author":"Rucci","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1093\/annonc\/mdm086_bb0505","first-page":"5028","article-title":"C-Src tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis","volume":"63","author":"Myoui","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0510","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2174\/138161206776056092","article-title":"Treatment of PSA only recurrence of prostate cancer after prior local therapy","volume":"12","author":"Moul","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1093\/annonc\/mdm086_bb0515","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1586\/14737140.6.4.595","article-title":"Management of prostate cancer. Part 2: localized and locally advanced disease","volume":"6","author":"Sooriakumaran","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdm086_bb0520","doi-asserted-by":"crossref","first-page":"8242","DOI":"10.1200\/JCO.2005.03.3092","article-title":"Chemotherapy for hormone-refractory prostate cancer: now it's a question of \u201cwhen?\u201d","volume":"23","author":"Ryan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm086_bb0525","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1056\/NEJMoa043739","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"352","author":"Bill-Axelson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm086_bb0530","doi-asserted-by":"crossref","first-page":"8165","DOI":"10.1200\/JCO.2005.03.3134","article-title":"Active surveillance for prostate cancer: for whom?","volume":"23","author":"Klotz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm086_bb0535","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm086_bb0540","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.292.7.821","article-title":"6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial","volume":"292","author":"D'Amico","year":"2004","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdm086_bb0545","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1093\/annonc\/mdm086_bb0550","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3322\/canjclin.55.5.300","article-title":"Advances in prostate cancer chemotherapy: a new era begins","volume":"55","author":"Pienta","year":"2005","journal-title":"CA Cancer J Clin"},{"issue":"June 20 Suppl","key":"10.1093\/annonc\/mdm086_bb0555","first-page":"231s","article-title":"A meta-analysis of individual patient data from randomized trials assessing chemotherapy with and without estramustine in patients with castration-refractory prostate cancer","volume":"24","author":"Fizazi","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1093\/annonc\/mdm086_bb0560","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm086_bb0565","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm086_bb0570","article-title":"Src as a novel therapeutic target in ovarian carcinoma","volume":"47","author":"Han","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0575","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1158\/1078-0432.CCR-04-0621","article-title":"Inhibition of Src tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice","volume":"10","author":"Yezhelyev","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0580","article-title":"Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma","volume":"47","author":"Lesslie","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0585","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/1078-0432.CCR-05-0622","article-title":"Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src\/Abl inhibitors are compatible with imatinib","volume":"11","author":"O'Hare","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0590","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CGC.2006.n.004","article-title":"The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel","volume":"4","author":"Saad","year":"2006","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 9","key":"10.1093\/annonc\/mdm086_bb0595","article-title":"Denosumab suppresses bone turnover in patients (pts) with bone metastases and elevated bone turnover markers (BTM) while receiving intravenous bisphosphonate (IV BP) therapy","volume":"17","author":"Fizazi","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm086_bb0600","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2174\/1381612043384457","article-title":"Src: regulation, role in human carcinogenesis and pharmacological inhibitors","volume":"10","author":"Tsygankov","year":"2004","journal-title":"Curr Pharm Des"},{"key":"10.1093\/annonc\/mdm086_bb0605","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.2174\/1381612033454126","article-title":"Src family kinases: potential targets for the treatment of human cancer and leukemia","volume":"9","author":"Warmuth","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1093\/annonc\/mdm086_bb0610","first-page":"729","article-title":"Novel bone-targeted Src tyrosine kinase inhibitor drug discovery","volume":"6","author":"Shakespeare","year":"2003","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1093\/annonc\/mdm086_bb0615","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1158\/0008-5472.CAN-04-2484","article-title":"SKI-606, a Src\/Abl inhibitor with in vivo activity in colon tumor xenograft models","volume":"65","author":"Golas","year":"2005","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0620","first-page":"2430","article-title":"Src family kinase inhibitor PP2 restores the E-cadherin\/catenin cell adhesion system in human cancer cells and reduces cancer metastasis","volume":"8","author":"Nam","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0625","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual Src\/Abl kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0630","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm086_bb0635","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/sj.pcan.4500750","article-title":"Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer","volume":"7","author":"Zhang","year":"2004","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1093\/annonc\/mdm086_bb0640","first-page":"173","article-title":"Evaluation of anti-osteoclastic activity of the novel, oral multi-targeted kinase inhibitor dasatinib (BMS-354825)","author":"Luo","year":"2005","journal-title":"Proceedings of the Molecular Targets and Cancer Therapeutics meeting"},{"issue":"June 20 Suppl","key":"10.1093\/annonc\/mdm086_bb0645","first-page":"339s","article-title":"Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 \u2018START-C\u2019 Study","volume":"24","author":"Hochhaus","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"issue":"June 20 Suppl","key":"10.1093\/annonc\/mdm086_bb0650","first-page":"338s","article-title":"Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial","volume":"24","author":"Shah","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1093\/annonc\/mdm086_bb0655","article-title":"The discovery of AZD0530: a novel, oral, highly selective and dual-specific inhibitor of the Src and Abl family kinases","volume":"46","author":"Hennequin","year":"2005","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0660","article-title":"Inhibition of osteoclastic bone resorption by the novel, potent, and selective c-Src\/Abl kinase inhibitor","volume":"46","author":"Mullender","year":"2005","journal-title":"AZD0530. Proc Am Assoc Cancer Res"},{"issue":"June 1 Suppl","key":"10.1093\/annonc\/mdm086_bb0665","first-page":"223s","article-title":"Phase I ascending single and multiple dose studies to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, dual-specific Src-Abl inhibitor","volume":"23","author":"Lockton","year":"2005","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"issue":"June 1 Suppl","key":"10.1093\/annonc\/mdm086_bb0670","first-page":"202s","article-title":"The effect of AZD0530, a highly selective, orally available Src\/Abl kinase inhibitor, on biomarkers of bone resorption in healthy males","volume":"23","author":"Eastell","year":"2005","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"issue":"June 20 Suppl","key":"10.1093\/annonc\/mdm086_bb0675","first-page":"603s","article-title":"A phase I study examining weekly dosing and pharmacokinetics (PK) of a novel spectrum selective kinase inhibitor, XL999, in patients (pts) with advanced solid malignancies (ASM)","volume":"24","author":"Cooper","year":"2006","journal-title":"J Clin Oncol (ASCO Annual Meeting Proceedings)"},{"key":"10.1093\/annonc\/mdm086_bb0680","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0685","first-page":"4244","article-title":"Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases","volume":"62","author":"Wisniewski","year":"2002","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdm086_bb0690","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood-2002-01-0288","article-title":"Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases","volume":"101","author":"Warmuth","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdm086_bb0695","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/sj.onc.1204296","article-title":"UCS15A, a non-kinase inhibitor of Src signal transduction","volume":"20","author":"Sharma","year":"2001","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdm086_bb0700","first-page":"244","article-title":"A new class of small-molecule therapeutics for osteolytic bone metastasis: discovery of novel bone-targeted src tyrosine kinase inhibitors having potent in vitro and in vivo activities","volume":"22","author":"Sawyer","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm086_bb0705","article-title":"Discovery of novel dual action Src kinase inhibitors demonstrating anti-resorptive and bone formation activities in vitro and in vivo","author":"Xing","year":"2002","journal-title":"Proceedings of the Annual Meeting of the American Society for Bone and Mineral Research"},{"key":"10.1093\/annonc\/mdm086_bb0710","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/1078-0432.CCR-05-2692","article-title":"Treatment for advanced tumors: Src reclaims center stage","volume":"12","author":"Summy","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/18\/11\/1765\/572232\/mdm086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T12:02:35Z","timestamp":1628769755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419411307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":141,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0923753419411307"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm086","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}